ARCHIVES

DRG Executives Names By DeVita as Director Of DEA; Other Sections Reportedly Made, Not Yet Approved

This article is from The Cancer Letter archive.

Vol. 07 No. 31 | July 31, 1981

Download PDF Visit The Full Archive

Related Articles

Laertrile Clinical Study Provides Solid Evidence: It Is Useless

May 8, 1981

Guest Editorial: Even Slam-Dunk Applications Can Benefit From Public Scrutiny and Discussion at ODAC

August 10, 2012

Nexavar Phase III Trial Fails To Meet Primary Endpoint

June 29, 2012

Also NCI requests $6.2 billion in FY2005 Bypass Budget.

January 2, 2004

In Brief: Treatment Reorganization Plan Due In November, Rauscher Says; Panel To Review Clinical Activities

June 27, 1975

City of Hope CEO Michael Friedman: Cancer Centers Must Adapt; “Not Losing Sleep” Over Sequestration

April 5, 2013